Last $2.93 USD
Change Today +0.32 / 12.26%
Volume 2.2M
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

invivo therapeutics holdings (NVIV) Snapshot

Open
$2.66
Previous Close
$2.61
Day High
$2.98
Day Low
$2.65
52 Week High
02/27/15 - $2.98
52 Week Low
09/10/14 - $0.47
Market Cap
297.5M
Average Volume 10 Days
1.1M
EPS TTM
$-0.16
Shares Outstanding
101.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INVIVO THERAPEUTICS HOLDINGS (NVIV)

Related News

No related news articles were found.

invivo therapeutics holdings (NVIV) Related Businessweek News

No Related Businessweek News Found

invivo therapeutics holdings (NVIV) Details

Invivo Therapeutics Holdings Corp., a development stage biomaterials and biotechnology company, focuses on developing and commercializing technologies for the treatment of spinal cord injuries (SCI). The company is developing a biocompatible Neuro-Spinal Scaffold to treat acute SCI; and biocompatible Neuro-Spinal Scaffold Plus Stem Cells to treat chronic SCI. Its proprietary technologies incorporate intellectual property licensed under exclusive, worldwide license from Children’s Medical Center Corporation and the Massachusetts Institute of Technology, as well as intellectual property that has been developed internally in collaboration with advisors and partners. The company was founded in 2005 and is based in Cambridge, Massachusetts.

45 Employees
Last Reported Date: 03/17/14
Founded in 2005

invivo therapeutics holdings (NVIV) Top Compensated Officers

Chief Financial Officer
Total Annual Compensation: $1.0K
Compensation as of Fiscal Year 2013.

invivo therapeutics holdings (NVIV) Key Developments

InVivo Therapeutics Holdings Corp. Announces Froedtert & the Medical College of Wisconsin as New Clinical Trial Site for Neuro-Spinal Scaffold

InVivo Therapeutics Holdings Corp. announced that Froedtert & the Medical College of Wisconsin (MCW) Froedtert Hospital in Milwaukee, WI has been added as a clinical site in the company’s ongoing IDE pilot study of its Neuro-Spinal Scaffold in patients with acute spinal cord injury (SCI). Froedtert Hospital houses the only adult Level 1 trauma center in eastern Wisconsin and receives referred spinal cord injury patients from Wisconsin, northern Illinois, and northern Michigan. Shekar Kurpad, MD, PhD, professor of neurosurgery at MCW and director of the Spinal Cord Injury Center and Spine Surgery Fellowship at Froedtert Hospital, has been named Principal Investigator at the site. On January 22, 2015, InVivo announced enrollment of its second patient in the study at its clinical site, Carolinas Medical Center in Charlotte, NC. InVivo’s patient was enrolled in October 2014 at the Barrow Neurological Institute at St. Joseph’s Hospital and Medical Center in Phoenix, AZ. This is the company’s first clinical study of its investigational degradable polymer Neuro-Spinal Scaffold. The IDE pilot study has been approved by the U.S. Food and Drug Administration (FDA) and is intended to capture preliminary safety and effectiveness data of the Neuro-Spinal Scaffold in five subjects with acute thoracic spinal cord injury. InVivo then expects to conduct a pivotal study to obtain FDA approval to commence commercialization under a Humanitarian Device Exemption (HDE).

InVivo Therapeutics Holdings Corp. Announces Executive Changes

InVivo Therapeutics Holdings Corp. announced the appointment of Lorianne Masuoka, MD, as Chief Medical Officer (CMO), effective March 2, 2015. She will be taking over for the interim CMO, Lou Vaickus, MD, who is also Founder & President of akta Pharmaceutical Development LLC. Prior to joining the InVivo team, Dr. Masuoka served as Senior Vice President and Chief Medical Officer at Cubist Pharmaceuticals from July 2013 until Jan. 2015.

InVivo Therapeutics Holdings Corp. Appoints Mark D. Perrin as Chairman of Board of Directors

InVivo Therapeutics Holdings Corp. announced the appointment of Mark D. Perrin as Chairman of InVivo’s Board of Directors, effective immediately. Perrin has served as a Board member and Chief Executive Officer of the company since January 2014. John A. McCarthy, Jr., current non-executive Chairman of the Board since September 2013, will remain on the Board and will continue to chair the Audit Committee.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVIV:US $2.93 USD +0.32

NVIV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NVIV.
View Industry Companies
 

Industry Analysis

NVIV

Industry Average

Valuation NVIV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 17.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INVIVO THERAPEUTICS HOLDINGS, please visit www.invivotherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.